KBP Biosciences Announces Support of Kidney Disease Clinical Trialists 2024 Workshop

Mar 27, 2024

KBP Biosciences Announces Completion of Enrollment to its Phase 3 CLARION-CKD Study of Ocedurenone for Uncontrolled Hypertension in Patients with Advanced Chronic Kidney Disease (CKD)

Nov 02, 2023

Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences

Oct 16, 2023

Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease

Apr 18, 2023

KBP Biosciences Announces First Patient Dosed in China

Mar 31, 2023

Ocedurenone Featured at Kidney Disease Clinical Trialists 2023 Workshop: Insights from the BLOCK-CKD Study

Mar 17, 2023

Ocedurenone (KBP-5074) Featured at the 19th Cardiovascular Clinical Trialists Forum: “New Targets for Resistant Hypertension and CKD” and “Epidemiology of Uncontrolled Hypertension in Patients with Stage 3b and Stage 4 Chronic Kidney Disease” were present

Feb 13, 2023

KBP Presents Ocedurenone Clinical Pharmacology Studies at ASN Kidney Week 2022

Dec 02, 2022

KBP Presents Ocedurenone Phase 2b Subgroup Analysis at AHA Scientific Sessions 2022

Dec 01, 2022

KBP Presents Results of the Hepatic Impairment Study and Drug-Drug Interaction Study of Ocedurenone (KBP-5074) at ASN Kidney Week 2022

Nov 30, 2022

KBP Biosciences Is Successfully Selected into the “Raffles Family Office · Hurun China Cheetahs 2021” List

Jan 30, 2022

KBP Biosciences Announces First Patient Dosed in KBP-5074 Global Phase 3 Study in Patients with Uncontrolled Hypertension and Advanced Chronic Kidney Disease

Jan 04, 2022

KBP Presented Efficacy Subgroup Analysis of KBP-5074 from BLOCK-CKD Study at Global CVCT Forum

Dec 11, 2021

KBP Biosciences Presentation at the 18th Global CardioVascular Clinical Trialist Forum To Present the New Treatment Options for Resistant Hypertension in CKD patients

Dec 10, 2021

Expert Opinion on Investigational Drugs Publishes "An Evaluation of KBP-5074 in Advanced CKD with Uncontrolled Hypertension"

Nov 30, 2021

KBP Participates in the 6th Kidney Disease Clinical Trialists Workshop

Nov 27, 2021

Results of the Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Compared with Eplerenone in a Rat Model of Mineralocorticoid-Induced Renal Injury Published in Frontiers in Pharmacology

Aug 06, 2021

Announcement of Chief Financial Officer Appointment

Jul 30, 2021

Announcement of Chief Operating Officer Appointment

Jul 30, 2021

KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension

Jun 22, 2021

KBP Biosciences Meets Primary Endpoint for BLOCK-CKD Phase 2b Study of KBP-5074 for the Treatment of Uncontrolled Hypertension in Advanced Chronic Kidney Disease Patients

Dec 07, 2020

KBP Biosciences Doses Final Patient in BLOCK CKD Phase 2b Study of KBP-5074

Aug 11, 2020

KBP Biosciences Announces Peer-Reviewed Publication of Trial Design Manuscript for Ongoing BLOCK CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension

Jun 30, 2020

KBP Biosciences’ KBP-5074 Appears Well Tolerated in a single dose PK Study in severe Chronic Kidney Disease (CKD) patients with and without hemodialysis

May 21, 2020

KBP Biosciences Completes Enrollment of BLOCK CKD Phase 2b Study of KBP-5074

May 20, 2020

KBP Biosciences Announces Publication of Potent In Vitro Activity of KBP-7072 Against Acinetobacter Baumannii

Apr 28, 2020